Mark Pharma News Today

Besides secondary shares sales, transaction includes primary funding that will aid the company to expand business.

Share this article Share this article LEXINGTON, Ky., April 30, 2021 /PRNewswire/ -- CereMark Pharma, LLC (CereMark) has been notified by the University of California Los Angeles (UCLA) that a U.S. patent is awarded to UCLA for Flornaptitril, a PET scan imaging radiopharmaceutical which is licensed exclusively to CereMark. Flornaptitril binds with both tau aggregates and beta amyloid plaque to enhance PET scan imaging of these pathological proteins in the brain. CereMark clinical studies show t...